Fund Holdings — Patient Square Capital LP

Total Portfolio Value:
$645.52M
Total Bought:
$152.78M
Total Sold:
$186.97M
Net Transaction:
-$34.19M
Securities
▲▼
SharesValue
Q1 2026
▲▼
Q2 2026
▲▼
Change
▲▼
Q1 2026
▲▼
Q2 2026
▲▼
Weight (%)
▲▼
Change
▲▼
Roivant Sciences Ltd.(ROIV)8,166,0478,020,928-145,119$226.20M$283.86M43.97%+$57.66M
Revolution Medicines, Inc.(RVMD)0276,000+276,000$0$51.69M8.01%+$51.69M
Mirum Pharmaceuticals, Inc.(MIRM)230,000260,500+30,500$21.25M$30.50M4.72%+$9.25M
ABIVAX Société Anonyme(ABVX)121,245206,500+85,255$13.50M$27.52M4.26%+$14.02M
BeOne Medicines AG(ONC)80,54290,020+9,478$23.92M$25.65M3.97%+$1.73M
PHARVARIS N V
COM
493,000671,209+178,209$13.93M$23.21M3.60%+$9.28M
argenx SE(ARGX)36,71823,000-13,718$26.81M$21.34M3.31%-$5.47M
United Therapeutics Corporation(UTHR)037,120+37,120$0$20.11M3.12%+$20.11M
Belite Bio, Inc(BLTE)116,684110,000-6,684$18.60M$16.94M2.62%-$1.67M
Cogent Biosciences, Inc.(COGT)596,000425,000-171,000$22.94M$16.45M2.55%-$6.49M
DBV TECHNOLOGIES S A693,534909,474+215,940$14.49M$14.92M2.31%+$427.4K
Xenon Pharmaceuticals Inc.(XENE)227,000220,000-7,000$13.20M$13.28M2.06%+$79.2K
BioNTech SE(BNTX)0134,429+134,429$0$12.51M1.94%+$12.51M
Arcus Biosciences, Inc.(RCUS)195,000355,800+160,800$4.21M$10.97M1.70%+$6.76M
ENLIVEN THERAPEUTICS INC200,000212,500+12,500$7.84M$10.78M1.67%+$2.94M
Dianthus Therapeutics, Inc.(DNTH)93,882108,000+14,118$7.88M$10.53M1.63%+$2.65M
ALLOGENE THERAPEUTICS INC3,450,0005,050,000+1,600,000$8.42M$10.50M1.63%+$2.09M
EYEPOINT INC795,000720,000-75,000$10.25M$10.30M1.59%+$48.5K
Arcutis Biotherapeutics, Inc.(ARQT)400,645370,000-30,645$9.44M$9.70M1.50%+$262.2K
C4 THERAPEUTICS INC01,608,815+1,608,815$0$7.51M1.16%+$7.51M
INVENTIVA SA01,967,171+1,967,171$0$7.44M1.15%+$7.44M
Kymera Therapeutics, Inc.(KYMR)100,00047,500-52,500$8.33M$5.45M0.84%-$2.88M
FAETH THERAPEUTICS INC0175,050+175,050$0$4.38M0.68%+$4.38M
ASSEMBLY BIOSCIENCES INC136,3150-136,315$3.78M$0—-$3.78M
Celcuity Inc.(CELC)95,0000-95,000$10.84M$0—-$10.84M
CYTOMX THERAPEUTICS INC.1,085,7900-1,085,790$5.10M$0—-$5.10M
Definium Therapeutics, Inc.(DFTX)331,0000-331,000$6.26M$0—-$6.26M
Harrow, Inc.(HROW)165,2090-165,209$5.83M$0—-$5.83M
Insmed Incorporated(INSM)157,5000-157,500$25.75M$0—-$25.75M
Legend Biotech Corporation(LEGN)990,0000-990,000$17.91M$0—-$17.91M
Merck & Co., Inc.(MRK)80,0000-80,000$9.62M$0—-$9.62M
Nektar Therapeutics(NKTR)210,0000-210,000$15.11M$0—-$15.11M
PERSPECTIVE THERAPEUTICS INC1,625,0000-1,625,000$6.78M$0—-$6.78M
PROTARA THERAPEUTICS INC1,030,8460-1,030,846$5.37M$0—-$5.37M
Spyre Therapeutics, Inc.(SYRE)1,0000-1,000$50.4K$0—-$50.4K
Page 1 of 1
Patient Square Capital LP — 13F Holdings — Q2 2026 | TickerTrail